Using SAFEPATH to Uncover a Novel Mechanism of Hepatotoxicity for Gefitinib
Hosseini-Gerami, L.; Masarone, S.; Lane, J.
Show abstract
This white paper details the research conducted by Ignota Labs using their advanced causal and explainable AI technology, SAFEPATH, to analyse the mechanisms of hepatotoxicity for two EGFR-TKI inhibitors, Erlotinib and Gefitinib, the latter having an as yet unknown mechanism of toxicity. The known mechanism of UGT1A1-mediated toxicity of Erlotinib was recovered, and a novel sphingolipid metabolism mechansim of toxicity of Gefitinib was hypothesised and subsequently experimentally validated. Crucially, we were also able to suggest the reason for the observed heterogeneous toxicity response to Gefitinib. This study exemplifies the potential of integrating AI tools with comprehensive datasets to improve drug safety and patient management.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Analysis of Mutations in Precision Oncology using The Automated, Accurate, and User-Friendly Web Tool PredictONCO 94%
- Drug repositoning or target repositioning: a structural perspective of drug-target-indication relationship for available repurposed drugs. 94%
- Network-based estimation of therapeutic efficacy and adverse reaction potential for prioritisation of anti-cancer drug combinations 94%
Similar papers in this journal
- Whole Exome Sequencing (WES) identifies Homozygous mutation in g.37429732G>A in GRHPR gene is responsible for early onset of nephrolithiasis in the population of West Bengal, India 91%
- Quantum Chemical Profiling of Protein Mutations via Fragment-Based DFT 90%
- Comparative Analysis of Electrostatic Models for Ligand Docking 89%
Similar papers in this journal
- Identification and characterization of metabolic subtypes of endometrial cancer using systems-level approach 90%
- Benchmark dataset for training machine learning models to predict the pathway involvement of metabolites 90%
- MetaboListem and TABoLiSTM: Two Deep Learning Algorithms for Metabolite Named Entity Recognition 90%
Similar papers in this journal
- Multiscale Analysis And Validation Of Effective Drug Combinations Targeting Driver Kras Mutations In Non-Small Cell Lung Cancer 97%
- DReAmocracy: A Method to Capitalize on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing 93%
- Protein profiling of WERI RB1 and etoposide resistant WERI ETOR reveals new insights into topoisomerase inhibitor resistance in retinoblastoma 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.